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1. Introduction
This international consensus statement of the European Heart
Rhythm Association (EHRA), Heart Rhythm Society (HRS), and Asia
Paciﬁc Heart Rhythm Society is intended to provide clinical
guidance for the management of patients with ventricular arrhyth-
mias (VAs). It summarizes the consensus of the international
writing group members and is based on a systematic review of
the medical literature regarding VAs.
The spectrum of VAs ranges from those that are benign and
asymptomatic to those that produce severe symptoms including
sudden cardiac death (SCD). In addition, many patients exhibit
multiple forms of VAs over time. Thus, clinicians who encounter
patients with VAs face important questions regarding which
diagnostic tests are needed and which treatments, if any, should
be offered. The Writing Committee recognizes that the manner in
which patients present with VAs varies greatly. The electrocardio-
graphic recording of a VA may be the ﬁrst and only manifestation
of a cardiac abnormality; alternatively, patients with a prior dia-
gnosis of cardiac disease may later develop these arrhythmias.
Thus, the speciﬁc arrhythmia and the underlying structural heart
disease (SHD), if any, may have important prognostic and treat-
ment implications.
This document addresses the indications for diagnostic testing,
the present state of prognostic risk stratiﬁcation, and the treat-
ment strategies that have been demonstrated to improve the
clinical outcome of patients with VAs. In addition, this document
includes recommendations for referral of patients to centres with
specialized expertise in the management of arrhythmias. Wher-
ever appropriate, the reader is referred to other publications
regarding the indications for implantable cardioverter-deﬁbri-
llator (ICD) implantation [1,2], catheter ablation [3], inherited
arrhythmia syndromes [4,5], congenital heart disease (CHD) [6],
the use of amiodarone [7], and the management of patient with
ICD shocks [8], syncope [9], or those nearing end of life [10]. The
consensus recommendations in this document use the standard
Class I, IIa, IIb, and III classiﬁcation [11] and the corresponding
language: ‘is recommended’ for Class I consensus recommenda-
tion; ‘can be useful’ for a Class IIa consensus recommendation;
‘may be considered’ to signify a Class IIb consensus recommenda-
tion; ‘should not’ or ‘is not recommended’ for a Class III consensus
recommendation (failure to provide any additional beneﬁt and/or
may be harmful). The level of evidence supporting these recom-
mendations is deﬁned as ‘A’, ‘B’, or ‘C’ depending on the number of
populations studied, whether data are derived from randomized
clinical trials, non-randomized studies, or, in the absence of large
studies, the consensus opinions of experts from case studies
or standards of care. Most medical interventions to prevent
sudden death and to treat VAs were developed in an era when
patient cohorts were small and the accepted standards to demon-
strate effectiveness were lower than today. Many interventions to
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terminate or suppress VAs have since been used in many patients,
and over time different treatment ‘patterns’ have developed in
different regions of the world. The writing group has tried to
accommodate reasonable variations in treatment in our recom-
mendations, and have relied upon expert consensus for many of
the recommendations put forward in this document. This is
reﬂected by the relatively low level of evidence that supports
the majority of our recommendations. Each of the recommenda-
tions was voted upon by the Writing Committee and only those
where there was at least 80% agreement have been included.
The consensus group has approached VAs by whether they are
sustained or non-sustained. The ﬁrst part of this document deals
with non-sustained arrhythmias, discussed in two parts [prema-
ture ventricular complexes (PVCs) and non-sustained ventricular
tachycardia (NSVT)].
The consensus group believes that patients with non-sustained
VAs need a standardized diagnostic workup. This is summarized
here, and explained in the two sections.
Expert consensus recommendations on general diagnostic work-up
(1). All patients with documented non-sustained or sustained
VAs should have a resting 12-lead electrocardiogram (ECG)
and a transthoracic echocardiogram to detect underlying
heart disease including inherited and acquired
cardiomyopathies. Especially in patients in whom the
arrhythmia morphology suggests such a speciﬁc aetiology,
valvular and right heart morphology and function should be
assessed. (IIa) LOE B
(2). Repeat 12-lead ECGs should be considered whenever an
inherited arrhythmia syndrome with varying
electrocardiographic manifestations or a transient condition
(e.g. coronary spasm) is suspected. (IIa) LOE C
(3). In selected patients, and especially in those with sustained
arrhythmias, a second imaging modality (e.g. a magnetic
resonance study, stress testing with perfusion scanning, or
echocardiography) should be considered to detect subtle
SHD. (IIa) LOE B
(4). A test for myocardial ischaemia should be considered in all
patients with VAs in whom the clinical presentation and/or
the type of arrhythmia suggests the presence of coronary
artery disease. IIa LOE C
(5). The risk of cardiac events is often dictated by an underlying
heart disease rather than the arrhythmia. Therefore, optimal
treatment of underlying cardiovascular diseases and risk
factors is recommended. I LOE A
(6). Prolonged ECG monitoring by Holter ECG, prolonged ECG
event monitoring, or implantable loop recorders should be
considered when documentation of further, potentially
longer arrhythmias would change management. IIa LOE C
(7). In patients with incompletely characterized arrhythmias
with wide QRS complexes, both supraventricular and VAs
should be considered in developing a care plan. IIa LOE C
For treatment of patients with non-sustained VAs, we propose
the following consensus recommendations.
Expert consensus recommendations on non-sustained Vas
(1) Infrequent ventricular ectopic beats, couplets, and triplets
without other signs of an underlying SHD or an inherited
arrhythmia syndrome should be considered as a normal
variant in asymptomatic patients. IIa LOE C
(2) An invasive electrophysiological study (EPS) should be
considered in patients with signiﬁcant SHD and
non-sustained VAs especially if accompanied by unexplained
symptoms such as syncope, near-syncope, or sustained
palpitations IIa LOE C
(3) No treatment other than reassurance is needed for patients
with neither SHD nor an inherited arrhythmogenic disorder
who have asymptomatic or mildly symptomatic PVCs. I LOE C
(4) It is recommended to treat survivors of a myocardial
infarction (MI) and other patient with reduced left
ventricular (LV) function and non-sustained VAs with a beta-
blocker unless these agents are contraindicated. I LOE A
(5) A therapeutic trial of beta-blockers may be considered in
symptomatic patients with non-sustained VAs. IIb LOE C
(6) In suitable patients without SHD, a non-dihydropyridine
calcium channel antagonist may be considered as an
alternative to beta-blocker treatment. IIb C
(7) In patients who suffer from symptomatic non-sustained VAs
on an adequately dosed beta-blocker or a non-
dihydropyridine calcium channel antagonist, treatment with
an antiarrhythmic drug (AAD; amiodarone, ﬂecainide,
mexiletine, propafenone, sotalol) may be considered to
improve symptoms associated with arrhythmia episodes.
IIb LOE C
(a) Flecainide and propafenone are not recommended to
suppress PVCs in patients with reduced LV function
(unless caused by ventricular ectopy itself),
myocardial ischaemia, or myocardial scar. III LOE A
(b) Sotalol should be used with caution in patients with
chronic kidney disease and should be avoided in
patients with a prolonged QT interval at baseline or
with excessive prolongation of QT interval (40.50 s)
upon therapy initiation. I LOE B
(c) Amiodarone appears to have less overall pro-
arrhythmic risk than
other AADs in patients with heart failure and may be
preferred to other membrane-active AADs unless a
functioning deﬁbrillator has been implanted. IIb LOE C
(8) Catheter ablation may be beneﬁcial by improving symptoms
or LV dysfunction in patients suffering from frequent non-
sustained VAs (e.g. 4PVC 10 000 per 24 h) in patients with
signiﬁcant symptoms or LV dysfunction without another
detectable cause. IIa LOE B
(9) Amiodarone, sotalol, and/or other beta-blockers are useful
pharmacological adjuncts to implantation of a deﬁbrillator (e.
g. to reduce shocks) and to suppress symptomatic NSVT in
patients who are unsuitable for ICD therapy, in addition to
optimal medical therapy for patients with heart failure.
IIb LOE B
2. Premature ventricular complexes
Premature ventricular complexes (PVCs) are common both in
patients with and without SHD and may be asymptomatic even for
patients with high frequency of these beats. Other patients may be
highly symptomatic with relatively few ectopic beats [12].
Although a recent meta-analysis [13] of patients without clinically
apparent SHD demonstrated an increased incidence of adverse
events in patients with frequent PVCs, only one of the included
studies used echocardiography to establish structural disease. The
independent prognostic importance of PVCs in the presence of
structural disease is not clear. Early studies demonstrated an
association with increased cardiovascular mortality after MI
[14,15] and with increased total mortality in patients with LV
hypertrophy (LVH) [16]. However, these studies were observa-
tional and performed in an era prior to modern management [17].
In a study of patients with congestive heart failure [ejection
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fraction (EF) o35%], PVC frequency did not predict the risk of
sudden death and did not provide prognostic information beyond
other clinical variables [18].
2.1. Premature ventricular complex-induced cardiomyopathy
Several studies have demonstrated an association between
frequent PVCs and a potentially reversible cardiomyopathy, which
in selected patients resolves after catheter ablation [19–24]. The
number of PVCs/24 h that is associated with impaired LV function
has generally been reported at burdens above 15–25% of the total
cardiac beats, though this may be as low as 10% [21–30] (Table 1).
However, since PVCs may be the result of an underlying cardio-
myopathy, it may be difﬁcult to prospectively determine which of
these sequences is operative in a given patient [31]. Importantly,
the vast majority of patients with frequent PVCs will not go on to
develop cardiomyopathy but currently available data do not allow
for accurate risk prediction. A recent longitudinal study followed
239 patients with frequent PVCs (41000 per day) and no SHD
[echo and magnetic resonance imaging (MRI)] for 5.6 years with
no adverse cardiac events and no decline in overall LV ejection
fraction (LVEF) [32].
2.2. Diagnostic evaluation
2.2.1. Electrocardiogram and ambulatory monitoring
The presence of at least some PVCs during 24 h ambulatory
monitoring is extremely common and may be considered
normal. Because the ﬁnding of PVCs during 24 h ambula-
tory monitoring is very likely, any conclusion that they are
related to symptoms requires careful correlation. In two stu-
dies in which SHD was rigorously excluded, only 2 and 4% had
0.50 or 0.100 PVCs/24 h, respectively [33,34]. The vast majority
of patients without SHD who have PVCs have a benign prog-
nosis. An exception may be a very small subset of patients with
PVCs that have a short coupling interval (o300 ms) between
the premature and the preceding beats, a ﬁnding which
suggests the short QT syndrome and increases the risk of
malignant Vas [35]. It should be emphasized that this is a very
small minority of patients with PVCs. As with other VAs, the
ﬁrst step in the evaluation of a patient with PVCs is to
determine the presence or absence of SHD (Figs. 1 and 2). For
patients with arrhythmic or other cardiac symptoms, a resting
12-lead ECG is very helpful to evaluate the presence of
myocardial scar (Q-waves or fractionated QRS complexes),
the QT interval, ventricular hyper-trophy, and other evidence
Table 1
PVC burden associated with LV dysfunction.
n %LVd %VEs LVd %VEs normal LV P Predictive PVC burden
Ban et al. [21] 127 (28 LVd) 22 31711% 22710% 0.001 26%
Deyell et al. [26] 90 (24 LVd) 27 32712% 27712% 0.077 –
Munoz et al. [27] 70 (LVd 17) 24 29715% 17714% 0.004 10% RV; 20% LV
Olgun et al. [28] 51 (21 LVd) 41 30711% 14715% 0.0001 –
Hasdemir et al. [29] 249 (17 LVd) 7 2979% 877% 0.001 16%
Baman et al. [30] 174 (57 LVd) 33 33713% 13712% 0.0001 24%
Kanei et al. [31] 108 (21 LVd) 19 13711%a 779%a 0.004 –
Lowest PVC count associated with LV dysfunction was 10% (Baman).
LV, left ventricle; LVD, left ventricular dysfunction; PVC, premature ventricular complexes; VE, ventricular ectopic.
a Assuming 100 000 beats/24 h.
SHDa
Medical treatment
Catheter ablation
Consider if:
Failed/intolerant/declined medical Rx,
Single/dominant PVC morphology,
Probable reversible LV dysfunction
Continued PVC symptoms
Reassurance re PVCs
Rx for SHDb
Reassurance
Possible reversible
LV dysfunction
(consider MRI-DEc) 
- Ongoing PVC symptoms
- PVC interference with CRT
LV dysfunction
and high PVC burden
No SHD
History and PE
ECG
Echo
Amb monitoring
Family history
Assess PVC
burden
>10 000
PVCs/24 h
<10,000
PVCs/24 hr
Treat PVCs
No evidence of
SHD or sustained VAs
Abnormal
basic evaluation
Fig. 1. Management of PVCs. a. See table for deﬁnitions of structural heart disease; b. Medical therapyþ ICD; c. Absence of high scar burden suggests reversibility. CRT,
cardiac resynchronisation therapy; ICD, implantable cardioverter-deﬁbrillator; LV, left ventricular; MRI-DE, magnetic resonance imaging with delayed enhancement; PE,
physical examination; PVC, premature ventricular complexes; Rx, therapy; SHD, structural heart disease; VAs, ventricular arrhythmias.
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of SHD. An echocardiogram provides assessment of right
ventricular (RV) and LV structure and function, valvular
abnormalities, and pulmonary artery systolic pressure and is
recommended for patients with symptomatic PVCs, a high
frequency of PVCs (410% burden), or when the presence of
SHD is suspected.
2.2.2. Exercise testing
For selected patients, especially when there is a suggestion of
symptoms associated with exercise, exercise stress testing should
be considered to determine whether PVCs are potentiated or
suppressed by exercise, to assess whether longer duration VAs
are provoked. A negative exercise test can decrease the proba-
bility that catecholaminergic polymorphic ventricular tachycardia
(CPVT) is the underlying cause. Premature ventricular complexes
that worsen with exercise should prompt further investigation as
these patients are more likely to require treatment.
2.2.3. Imaging investigations
Although the majority of patients with PVCs can be accurately
assessed with a 12-lead ECG and echocardiography, contrastenhanced
MRI may provide additional diagnostic and prognostic data when the
presence or absence of SHD remains in doubt [36]. While there are no
large-scale studies investigating which patients should undergo MRI,
the management of several forms of SHD associated with PVCs may
be guided by MRI, including dilated cardiomyopathy, hypertrophic
cardiomyopathy (HCM), sarcoidosis, amyloidosis, and arrhythmogenic
right ventricular cardiomyopathy (ARVC) [37–39]. In these conditions,
the presence of ventricular wall motion abnormalities or myocardial
scar detected by delayed gadolinium enhancement may provide
useful prognostic information. In selected patients for whom the
diagnosis of ARVC is suspected, the signal-averaged ECG (SAECG) may
provide useful information and forms a minor diagnostic criterion for
this disorder.
2.3. Treatment
2.3.1. Indications for treatment in patients without structural heart
disease
In the absence of SHD, the most common indication for treating
PVCs remains the presence of symptoms that are not improved by
explanation of their benign nature and reassurance from the
physician. In addition, some patients may require treatment for
frequent asymptomatic PVCs if longitudinal imaging surveillance
reveals an interval decline in LV systolic function or an increase in
chamber volume. For patients with 410 000 PVCs/24 h, follow-up
with repeat echocardiography and Holter monitoring should be
considered. In patients with fewer PVCs, further investigation is
only necessary should symptoms increase. It should also be
recognized that PVC burden often ﬂuctuates over time.
2.3.2. Indications for treatment in patients with structural heart
disease
In patients with SHD, symptoms form the primary grounds for
considering whether treatment is indicated. Elimination of high
burden PVCs (410%) in patients with impaired LV function can be
associated with signiﬁcant improvement of LV function, [19,20]
even when signiﬁcant scarring is present [22,23]. Catheter ablation
may also be helpful when frequent PVCs interfere with cardiac
resynchronization therapy [40].
2.4. Management of premature ventricular complexes (options)
2.4.1. Medical therapy
For patients without SHD and mild symptoms, the ﬁrst step in
treatment of patients with PVCs is education of the benign nature of
this arrhythmia and reassurance. No large-scale randomized trials of
drug treatment for PVCs in the absence of heart disease have been
performed. For patients whose symptoms are not effectively managed
in this manner, a trial of beta-blockers or non-dihydropyridine calcium
Patient history
Prior diagnosis of SHD?
Risk factors for SHD?
Symptoms of SHD?
Non-cardiac disorders that may
affect the heart?
Syncope?
Family Hx SCD?
Family Hx of SHD?
Physical examination
evidence for SHD?
Electrocardiogram
baseline 12-lead ECG
12-lead ECG during VA
ECG monitoring
Echocardiogram
Exercise testing / Imaging
coronary arteriography if
indicated
Structural heart
disease
No structural
heart disease
Advanced imaging
MRI-DE
CT
coronary arteriography
Abnormal basic evaluation Normal basic evaluation
Inconclusive 
basic evaluation
Abnormal advanced imaging Normal advanced imaging
Fig. 2. Evaluation for the presence or absence of structural heart disease. CT, computed tomography; MRI-DE, magnetic resonance imaging with delayed enhancement; VA,
ventricular arrhythmia.
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antagonists may be considered though the efﬁcacy of these agents is
quite limited with only 10–15% of patients achieving 490% PVC
suppression, [41] similar to placebo.[42] It should also be recognized
that the data supporting the use of calcium blockers are less than for
beta-blockers and that these agents may themselves produce signiﬁ-
cant symptoms. While membrane-active AADs are more effective to
suppress PVCs, the risk–beneﬁt ratio has not been carefully evaluated
in patients without SHD. Nevertheless, these agents are highly
effective and may signiﬁcantly improve symptoms in markedly
symptomatic patients. Because these agents may increase the risk of
mortality in patients with signiﬁcant SHD, perhaps with the exception
of amiodarone, caution is advised before using them for PVC suppres-
sion [41,43].
2.4.2. Catheter ablation
Randomized trials of PVC suppression with catheter ablation have
not been performed. However, multiple studies indicate high efﬁcacy
of ablation with PVC elimination in 74–00% of patients [44–57].
However, these studies have typically included highly symptomatic
patients typically with a very high burden of PVCs. Thus, catheter
ablation should only be considered for patients who are markedly
symptomatic with very frequent PVCs. In addition, procedural success
may be dependent on site of origin with lower efﬁcacy reported for
coronary venous and epicardial foci than for other sites [49,58].
Although complete PVC elimination is the goal of ablation, it should
be noted that partial success may still be associated with signiﬁcant
improvement in LV systolic function. The efﬁcacy of catheter ablation
may be reduced for patients with multiple morphologies of PVCs or
those for whom the clinical PVC morphology cannot be induced at the
time of the procedure. The published complication rates of catheter
ablation for PVC suppression are generally low (1%). Catheter
ablation of PVCs is recommended for highly selected patients
who remain very symptomatic despite conservative treatment
or for those with very high PVC burdens associated with a
decline in LV systolic function.
3. Non-sustained ventricular tachycardia
Although several different deﬁnitions have been used, [59]
NSVT is deﬁned as runs of beats arising from the ventricles with
duration between 3 beats and 30 s and with cycle length
of o600 ms (4100 b.p.m.) [60]. Similar to PVCs, NSVT is a
relatively common ﬁnding in patients with either structurally
normal or abnormal hearts[59,61,62]. Non-sustained ventricular
tachycardia is found in nearly 6% of patients evaluated for
palpitations [63]. Diagnostic and therapeutic considerations for
NSVT are included in several [3,60,64] recent guideline and
consensus documents. In general, therapy for the underlying
cardiac disease is indicated rather than for the arrhythmia itself.
However, the ﬁnding of NSVT should always trigger further evaluation
of the patient and a practical approach can be usefully divided into a
general approach (Table 2), patients with an apparently normal heart
(Table 3) and those with SHD (Table 4).
3.1. Non-sustained ventricular tachycardia in the structurally
normal heart
Exercise-related NSVT is relatively common and appears to
be associated with a worse prognosis when it occurs during
recovery [65,66]. Polymorphic NSVT requires extensive evalua-
tion in both symptomatic and asymptomatic patients with
careful assessment for the presence of coronary ischaemia.
An important inherited arrhythmia which may present as
Table 2
Evaluation of patients with non-sustained ventricular tachycardia.
Standard evaluation
History
Prior cardiovascular disease?
Hypertension, known cardiac disease?
Syncope or near-syncope?
Sustained palpitations?
Relation of symptoms to exercise?
Family history
SCD, inherited arrhythmia syndromes, coronary artery disease, cardiomyopathy?
Medications
QT prolonging drugs, sodium channel blockers, drug interactions?
Physical examination
Evidence of cardiac disease?
Twelve-lead ECG
Q-waves, ischaemic changes, prolonged or fractionated QRS, QT prolongation or shortening, ST elevation V1 – V3, early repolarization, epsilon waves, or anterior
T-wave inversion
Echocardiography
Ventricular chamber dimensions and thickness, wall motion, systolic and diastolic function, valvular function, congenital anomalies, pulmonary arterial systolic
pressure
Laboratory
Serum electrolytes, renal function
Further evaluation
Exercise testing
Suspicion of coronary artery disease, exercise-related symptoms, borderline QT interval
Coronary arteriography
Suspicion of coronary artery disease or coronary artery anomaly
Cardiac MRI
Suspicion of ARVC, HCM, cardiac sarcoidosis, congenital anomalies
Genetic testing
Suspicion of inherited arrhythmia syndrome, family history of inherited arrhythmia syndrome
Electrophysiological testing
Sustained palpitations without diagnosis, suspicion of AV block, coronary artery disease with NSVT, and moderate LV dysfunction
ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; HCM, hypertrophic cardiomyopathy; LV, left ventricular; MRI, magnetic resonance imaging;
NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death.
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exercise-induced NSVT is CPVT [72,73]. This condition is
typically manifested by polymorphic or bidirectional VT which
are triggered by sympathetic stimulation and exercise (com-
monly occurring at an exercise level of 120–130 b.p.m.) and is
associated with an increased risk of sudden death. The
underlying mechanism of CPVT is calcium overload leading to
delayed afterdepolarizations as a result of mutations in the
genes coding for ryanodine receptor or calsequestrin proteins.
Non-sustained ventricular tachycardia is a relatively common
ﬁnding among athletes [67,68]. Other causes of NSVT in the
Table 3
Non-sustained ventricular tachycardia with apparent normal heart.
NSVT clinical
presentation
ECG Risk of sudden
cardiac death
Diagnostic evaluation Alternative
Diagnostic
considerations
Treatment Treatment to be
considered
Key references
Typical RVOT LBBB, inf axis,
axis transition
V3–V4
Very rare Standard Differentiate
from ARVC
Beta-blocker,
verapamil, IC drugs
with symptoms
Catheter ablation Latif et al.[63]
Typical LVOT Inferior axis,
transition oV3
Very rare Standard RVOT VT Beta-blocker,
verapamil, IC drugs
with symptoms
Catheter ablation Latif et al. [63]
Idiopathic
reentrant LV
tachycardia
RBBB, LS axis Very rare Standard EP testing Ischaemic heart
disease, CM
Verapamil if
symptomatic
Catheter ablation Latif et al. [63]
Other focal VT Multiple
morphologies,
monomorphic
Uncommon Exercise testing or
catecholamine
stimulation
Ischaemic heart
disease, CM
Beta-blocker for the
arrhythmia
Catheter ablation Latif et al. [63]
Exercise Multiple Increased risk when
NSVT in recovery
Ischaemic heart disease,
cardiomyopathy
CPVT Underlying disease Beta-blockers,
ﬂecainide
Jouven et al.
[66] and Frolkis
et al. [67]
Athlete Multiple If it disappears with
increased exercise
low risk
Evaluate for latent HCM
or ischaemic heart
disease
HCM No treatment training
can continue
None Bifﬁ et al.
[68,69]
Hypertension
valvular
disease
Multiple
morphology
As without
arrhythmia
Consider ischaemic heart
disease
Ischaemic heart
disease, CM
Treat HTN Beta-blocker
Polymorphic
VT
Polymorphic High Evaluated for CAD, CPVT,
inherited arrhythmia
syndromes
Purkinje ﬁbre
triggering focus
Underlying disease Revascularization, ICD,
beta-blocker, catheter
ablation
Zipes et al. [61]
TdP VT Long QT, TdP High Medications, congenital
LQTS
Medications,
Kþ , Mgþ þ ,
Caþ þ
Stop medications,
correct electrolytes
ICD, beta-blocker Sauer and
Newton–Cheh
[70]
ARVC, arrhythmogenic right ventricular cardiomyopathy; CAD, coronary artery disease; CM, cardiomyopathy; CPVT, catecholaminergic polymorphic ventricular tachycardia;
HCM, hypertrophic cardiomyopathy; HTN, hypertension; ICD, implantable cardioverter-deﬁbrillator; LS, left-superior; LV, left ventricular; LVOT, left ventricular outﬂow tract;
NSVT, non-sustained ventricular tachycardia; RBBB, right bundle branch block; RVOT, right ventricular outﬂow tract; TdP, torsade de pointes; VT, ventricular tachycardia.
Table 4
Non-sustained ventricular tachycardia in structural heart disease.
Clinical setting Risk of
sudden
Cardiac death
Arrhythmia
specialist
evaluation
Diagnostic
evaluation
Diagnostics to be
considered
Treatment Treatment to be
considered
Key references
ACS within 48 h No increased
risk
No Coronary artery
disease
Monitoring Beta-blockers Hohnloser et al.
[71]
ACS after 48 h Risk increased Yes Consider EPS if
moderate LV
dysfunction
Continued evaluation
for repetitive
arrhythmias
Beta-blockers ICD Zipes et al. [61]
Previous MI, EF 31–40 Increased risk Yes EPS ICD
withinducible
VT/VF
ICD, see relevant guidelines Zipes et al. [61]
Previous MI, EFr30
Chronic heart failure,
EFr30
Increased risk Yes Non-driven by
arrhythmia
ICD Antiarrhythmic medical
therapy or ablation with
symptoms
Zipes et al. [61]
Syncope with chronic
CAD, EF440
Increased risk Yes EP testing,
ischaemia testing
Monitoring ICD with
inducible VT/VF
Additional Antiarrhytmic
therapy or ablation
Zipes et al. [61]
Non-ischaemic dilated
CM
Uncertain Yes Uncertain EP testing Uncertain ICD, see relevant guidelines Zipes et al. [61]
HCM Increased risk Yes Echo, MRI MRI-DE Beta-blocker, ICD Zipes et al. [61]
LQTS Increased risk Yes Genetic screening Beta-blocker ICD Zipes et al. [61]
Short QT syndrome Increased risk Yes Provocative testing
Brugada syndrome Increased risk Yes Provocative testing Genetic screening With syncope or
cardiac arrest:
ICD
Quinidine Aliot et al. [3]
ER syndrome Increased risk Yes
CAD, coronary artery disease; CM, cardiomyopathy; EF, ejection fraction; EP, electrophysiology; EPS, electrophysiological study; ER, early repolarisation; HCM, hypertrophic
cardiomyopathy; ICD, implantable cardioverter-deﬁbrillator; LV, left ventricular; MI, myocardial infarction; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
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Left Coronary Cusp VT
Fig. 3. (A) Right ventricular (RV) outﬂow tract VT. (B) Left coronary cusp VT.
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absence of SHD include QT interval prolongation caused by
mutations in proteins regulating repolarizing currents drugs
(LQTS) or electrolyte abnormalities. Athletes with NSVT should
be evaluated for the presence of HCM, a diagnosis which may
overlap with some degree of LVH as an adaptation to exercise.
Because of this challenging distinction, expert consultation
should be obtained if this diagnosis is suspected. Although
only limited data are available regarding the signiﬁcance of
NSVT in athletes without a structural cardiac disease, discon-
tinuation of training is not generally recommended.
3.2. Non-sustained ventricular tachycardia in structural heart
disease
Non-sustained ventricular tachycardia is common in ischaemic
heart disease and can be recorded in 30–80% of patients during long-
term ECG monitoring where it is usually asymptomatic [60]. No
studies have demonstrated a mortality beneﬁt of suppressing NSVT
with either AADs or catheter ablation and treatment is usually not
indicated in asymptomatic patients. A range of studies have demon-
strated that NSVT occurring during the ﬁrst few days after an acute
coronary event has no adverse long-term prognostic signiﬁcance.
However, when NSVT occurs 48 h or more after MI, there is an
increased mortality and morbidity even when asymptomatic [74]. For
a patient with non-ischaemic dilated cardiomyopathy, the prognostic
signiﬁcance of NSVT is uncertain and no studies have provided precise
guidance for treatment in this group of patients [75].
The occurrence of NSVT in patients with an implanted ICD is
associated with an increased frequency of shocks and all-cause
mortality [76]. For these patients, programming the ICD to a long
VT detection time and a high ventricular ﬁbrillation (VF) detection
rate may be especially important [77,78].
3.3. Diagnostic evaluation
For patients with an apparently normal heart, the 12-lead ECG
should be scrutinized for evidence of typical outﬂow tract VT,
[53,54,56,62] (Fig. 3) polymorphic VT (PMVT), including torsades de
pointes (TdP), or an inherited arrhythmia syndrome, such as the long
QT, short QT, Brugada, or early repolarization syndromes (ERS) [4]
(Fig. 4). Outﬂow tract VAs typically have an inferior axis with either
RV or LV origin. When the precordial transition is oV3 and the ratio
of the R- and S-waves in lead V2 during PVCs or VT divided by this
ratio during sinus rhythm exceeds 0.6, a LV outﬂow tract origin is
strongly suggested. In addition to the ECG, an echocardiogram to
assess the presence or absence of SHD should also be considered for
all patients with NSVT. For cases where SHD is suspected but cannot
be deﬁnitively diagnosed with echocardiography, cardiac MRI may be
especially useful to conﬁrm the presence or absence of myocardial
scar or wall motion abnormalities. Classiﬁcation of NSVT should be
attempted using a scheme similar to Tables 3 and 4. Evaluation in
CHD is described in a separate section.
3.4. Treatment
3.4.1. Non-sustained ventricular tachycardia in the absence of
structural heart disease
Most short-lasting monomorphic NSVTs originate from the RV
or LV outﬂow tracts (Table 3 and Fig. 3). These arrhythmias only
require treatment if they are symptomatic, incessant, or produce
LV dysfunction. Sudden death is very rare in patients with outﬂow
tract VT. The treatment of these arrhythmias is either medical with
a beta-blocker, a non-hydropyridine calcium blocker, class IC
drugs, or with catheter ablation [60]. Non-sustained ventricular
tachycardia with a focal mechanism may also occur from the
papillary muscles and respond to beta-blockers or catheter abla-
tion [58,79,80]. In addition, reentrant LV VT utilizing false tendons
can be treated with verapamil, though with a relatively high
recurrence risk on oral therapy [71,81,82]. Catheter ablation is
effective for idiopathic reentrant LV VT and should be considered
even when this sustained arrhythmia is terminated by intravenous
verapamil. Catheter ablation can be recommended for patients
with idiopathic NSVT that is highly symptomatic and drug refrac-
tory, especially if it is exercise-induced.
3.4.2. Non-sustained ventricular tachycardia in patients with
structural heart disease
The recording of polymorphic NSVT should prompt a thorough
evaluation for the presence of coronary ischaemia as the primary
therapy for this arrhythmia should be directed to improving
coronary perfusion. If non-sustained PMVT can be classiﬁed as a
CPVT, the risk of life-threatening arrhythmia is high and beta-
blockade therapy with potential placement of an ICD is recom-
mended [4,83]. In cases of TdP VT, any medication or electrolyte
disturbance that prolongs repolarization should be addressed.
Although an ICD should be considered for all patients with a
signiﬁcantly reduced LVEF (o0.35), [84–86] there may be a role
for programmed electrical stimulation in selected patients with
NSVT and ischaemic heart disease who have less severe LV dysfunc-
tion (LVEFo0.40) [87,88]. Implantable cardioverter-deﬁbrillator
implantation is recommended in this group of patients if VF or
sustained VT is inducible with programmed electrical stimulation
[60]. Similarly, if NSVT is observed in a patient with a prior MI, a
history of syncope, and LVEF440%, EPS is generally recommended to
guide treatment, usually with ICD implantation, should sustained VT
be inducible. Non-sustained ventricular tachycardia in an asympto-
matic patient with a LVEF440% does not usually require speciﬁc
antiarrhythmic therapy, and the goal is optimized treatment of the
underlying heart disease. In the setting of HCM, ICD therapy is an
appropriate consideration if NSVT is present with or without other
major risk factors [60]. In general, AAD therapy may be considered for
patients with SHD who experience symptomatic, recurrent NSVT not
resolved by revascularization, optimization of medical therapy, or
treatment of reversible factors.
4. Sustained monomorphic ventricular tachycardia
Expert consensus recommendations on SMVT
(1) A 12-lead ECG should be recorded during sustained VTs
whenever possible and practical. I LOE B
(2) For patients with newly diagnosed sustained monomorphic
VT (SMVT) and no evidence of SHD on resting ECG or
echocardiography
II
V1
Long QT syndromes
Short QT syndromes
WPW syndrome
Brugada syndrome(s)
ARVC
HCM
Fig. 4. Electrocardiograms (ECGs) in long OT syndrome, short OT syndrome,
Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, hyper-
trophic cardiomyopathy, WPW syndrome.
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(a) cardiac MRI may provide additional information
(IIb), LOE B
(b) signal-averaged ECG may provide additional
information (IIb). LOE C
(c) exercise testing may provide additional information
(IIb). LOE B
(3) For patients with a wide QRS complex tachycardia in whom
the diagnosis is uncertain, an invasive EPS should be
considered to identify the tachycardia mechanism. (IIa) LOE C
(4) For patients with SHD and SMVT, an ICD is recommended in
the absence of contraindications. (I) LOE A
(5) For patients with SHD and recurrent SMVT, speciﬁc
treatment of Vas with AADs (amiodarone, mexiletine, or
sotalol), catheter ablation, and/or antitachycardia pacing
(ATP) from an ICD should be considered in addition to an ICD.
Treatment of the underlying SHD or ischaemia will in most
cases not be sufﬁcient to prevent monomorphic VT (MMVT)
recurrences. (IIa) LOE B
(6) For patients with an ICD as primary prophylaxis,
programming to a long VT detection interval and a high VF
detection rate should be considered. (IIa) LOE A.
Monomorphic VT is deﬁned as sustained when lasting longer
than 30 s or requires earlier intervention due to haemodynamic
instability [89]. Most commonly, sustained MMVT occurs in the
setting of diseased myocardium, but may also be idiopathic,
occurring in patients with no detectable myocardial disease.
4.1. Importance and prognosis
No structural disease—idiopathic ventricular tachycardia In the
absence of SHD, SMVT is generally associated with an excellent
prognosis [60,90–92]. The presence of syncope or PMVT is unusual
in the absence of SHD or an inherited arrhythmia syndrome.
Rarely, idiopathic VT can have a malignant clinical course, usually
with a very rapid rate or a short initiating coupling interval [93].
4.1.1. Sustained monomorphic ventricular tachycardia in patients
with structural heart disease
The large majority of patients with SMVT who present for therapy
have signiﬁcant SHD. The most frequent aetiology is ischaemic heart
disease, comprising 54–59% of patients for whom an ICD is implanted
[94] or who are referred for catheter ablation [92]. Sustained VT is
associated with increased mortality risk in the setting of reduced
ventricular systolic function [95–98]. The mortality risk attributable to
VT in patients with preserved ventricular function is less well deﬁned.
Implantable cardioverter-deﬁbrillator shocks are also associated with
inherent risk andmultiple studies have demonstrated that deﬁbrillator
shocks, both appropriate and inappropriate, are associated with
increased mortality and reduced quality of life [78,99–103]. The
association of ICD shocks and total mortality appears mainly to be a
function of worsening cardiac disease rather than a speciﬁc conse-
quence of shocks. Programming of ICDs with long VT detection times
prior to the delivery of antitachycardia therapies and rapid VF
detection rates reduces shocks and improves mortality in patients
receiving an ICD for primary prophylaxis [77]. The value of program-
ming a long VT detection time in patients with a history of sustained
MMVT or VF is less certain. Although it has not been determined
whether suppression of VT by either pharmacological means or
catheter ablation improves survival in patients with sustained MMVT,
treatment to avoid recurrent symptoms is appropriate and these
therapies may improve survival in patients presenting with recurrent
VT storm [104,105].
4.2. Diagnostic evaluation
4.2.1. Electrocardiogram
The key distinction to make in the investigation of SMVT is to
discern the presence or absence of SHD, see Table 2. A 12-lead ECG
Evaluate cardiac structure
and function
Treat SHD as appropriate
ICD if indicated
Beta-blockers,
antiarrhythmic drugs, or
catheter ablation:
may all be considered first line
(ICD required for rare
malignant idiopathic VT)
Non-Ischaemic
SHD
Optimize ICD
programming
antiarrhythmic drugs
preferred first line
No SHDSHD
Recurrent VT:
IIA
indication
Ischaemic SHD
Optimize ICD
programming
antiarrhythmic drugs or
catheter ablation may
be considered first line
VT
suppression
Single episode
VT: IIB
indication
VT
suppression
Catheter ablation
when drug-refractory Catheter ablation
when drug-refractory
Fig. 5. Sustained monomorphic ventricular tachycardia evaluation and management. ICD, implantable cardioverter-deﬁbrillator; SHD, structural heart disease; VT,
ventricular tachycardia.
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helps to conﬁrm the diagnosis of VT, [106–110] provide important
insight into the underlying mechanism (Tables 3 and 4), identify
the presence of SHD, [111] and suggest the site of origin. This is
especially important when catheter ablation is planned [112,113].
A resting ECG should be performed in all patients with sustained
VT. The presence of Q-waves or fragmentation of the QRS complex
suggests underlying structural disease (Fig. 5) [114,115].
4.2.2. Cardiac imaging
The presence of myocardial scar is more likely to be associated
with poorly tolerated VT, haemodynamic collapse, degeneration to
VF, and sudden death. In most cases, echocardiography can
adequately demonstrate myocardial structure and function. If
echocardiography is normal, more detailed imaging using cardiac
MRI can exclude less clearly evident myocardial scar, arrhythmo-
genic RV cardiomyopathy, non-ischaemic cardiomyopathy with
preserved EF, HCM, or cardiac sarcoidosis [116]. It may also be
helpful to reevaluate ventricular function when a patient with
previously known SHD presents with SMVT.
4.2.3. Signal-averaged electrocardiogram
An SAECG, recorded during the baseline rhythm may permit the
identiﬁcation of slow myocardial conduction by recording low-
amplitude potentials but does not help in scar localization. A negative
test has been associated with better prognosis [117] but with only
modest positive predictive value [118]. The SAECG may be most
useful in identifying ARVC where a positive test forms a minor
criterion in the diagnostic component for this disorder [39,119].
4.2.4. Invasive electrophysiological study
Patients presenting with syncope or sustained palpitations who
have evidence of myocardial scar as well as those with a wide-
complex tachycardia for whom the diagnosis of VT is not certain
may beneﬁt from a provocative EPS. Although the standalone
negative and positive predictive values of this testing are limited,
[88,120] inducible SMVT is highly associated with recurrent VT
and may provide clues to the cause of syncope or other symptoms
suggestive of a VA. Electroanatomical mapping of the RV has been
used to identify otherwise unapparent RV scar [121,122].
4.2.5. Testing for ischaemia
Transient myocardial ischaemia is an uncommon sole cause of
recurrent sustained VT that is monomorphic. Most patients with
coronary artery disease who develop sustained MMVT have a ﬁxed
region of myocardial scar that is a sequela of prior MI, often
occurring many years earlier [95–97]. Patients with a new pre-
sentation of sustained MMVT should have a thorough evaluation
to deﬁne the presence or absence of underlying heart disease,
which includes echocardiography, exercise testing, and stress/
perfusion imaging. For most patients where the coronary artery
disease is suspected as the underlying diagnosis, coronary angio-
graphy should be considered [123–126]. However, treatment of
ischaemia alone is unlikely to prevent recurrences of MMVT.
Cardiac MRI and positron emission tomograph – computed tomo-
graphy may provide evidence for myocardial scar that is not
evident with other imaging modalities and may be especially
useful to differential occult SHD from idiopathic VT [127].
4.3. Treatment
Acute therapy for sustained ventricular tachycardia Ventricular
ﬁbrillation should be immediately deﬁbrillated using a non-
synchronized mode. The use of intravenous amiodarone has been
associated with a higher survival probability than when lidocaine
is administered to patients resuscitated from VF [128]. The acute
treatment of sustained VT is largely based on the patient's
symptoms and haemodynamic tolerance of the arrhythmia. For
patients with sustained MMVT who are unconscious or who have
experienced haemodynamic collapse, direct current cardioversion
synchronized to the QRS on the surface ECG should be immedi-
ately performed. Patients who are conscious but have marked
hypotension or profound symptoms from VT should be given
prompt intravenous sedation and then cardioverted. A trial of
intravenous lidocaine (1 mg/kg) may be given as preparation is
made for sedation, though the efﬁcacy for termination of sustained
VT is only 15% [129]. For patients with sustained VT who are
haemodynamically stable or have only mild symptoms, a 12-lead
ECG should be recorded and carefully analysed before therapy is
initiated. For patients without SHD and a QRS morphology
suggesting an idiopathic outﬂow tract VT, a trial of a short-acting
intravenous beta-blocker may be useful to terminate VT. However,
for patients with SHD with sustained VT, the most efﬁcacious
pharmacological agent is intravenous amiodarone [129]. This
agent may be associated with hypotension if administered rapidly,
usually via a central venous catheter. These patients must be
continuously observed and intravenous sedation and cardiover-
sion should be readily available and applied if symptoms worsen
or haemodynamic deterioration occurs. Patients with TdP VT
should be cardioverted if the arrhythmia is sustained. For those
with recurrent non-sustained TdP VT, atrial pacing at a rate of at
least 90 b.p.m. is highly effective to prevent recurrences. Intrave-
nous isoproterenol can be useful to sup-press recurrent TdP or VF
in patients with the Brugada syndrome (BrS).
4.3.1. Pharmacological therapy for idiopathic ventricular tachycardia
The indication for treatment of idiopathic VT derives largely
from the symptom burden. Beta-blockade and non-hydropyridine
calcium channel blockade are low-risk therapies which have
modest effectiveness [130,131]. Antiarrhythmic drug therapy using
sotalol, ﬂecainide, mexiletine, propafenone, or amiodarone is more
effective, but carries the potential for pro-arrhythmic risk, and a
greater side-effect proﬁle [132]. Catheter ablation for idiopathic
ventricular tachycardia For focal VT with an ECG pattern highly
suggestive of right ventricular outﬂow tract (RVOT) VT, [113]
catheter ablation is highly successful and carries low procedural
risk. The most frequent limitation is the lack of VT inducibility
during the procedure. The success rate of ablation of outﬂow tract
VTs arising from non-RVOT sites may be somewhat lower and may
involve greater procedural complexity but should be considered.
Fascicular VT and focal VTs from non-outﬂow tract sites such as the
LV or RV papillary muscles may also be amenable to catheter
ablation, with the principal limitation being inducibility of the
arrhythmia and achieving adequate mapping and catheter contact
to abolish the VT [3,44–58,71,79,132–134]. In addition, it should be
appreciated that papillary muscle VT has a signiﬁcant risk of
recurrence after initially apparent successful catheter ablation.
4.3.2. Pharmacological therapy for ventricular tachycardia with
structural heart disease
The presence of SHD increases the risk of pro-arrhythmia from
membrane-active AADs, such that they are generally used only
with the added protection afforded by an ICD [43]. There is no
evidence that antiarrhythmic therapy alone improves survival in
patients with sustained MMVT [135–137]. Sotalol has been
demonstrated to reduce the frequency of sustained MMVT recur-
rences [138,139] in patients with SHD. In the OPTIC trial, sotalol
reduced all-cause ICD shocks at 1 year from 38.5% to 24.3% [hazard
ratio (HR) 0.61, P ¼ 0.055] [138]. A smaller study suggested that
sotalol was inferior to metoprolol [140]. In these trials, sotalol
was associated with a safety proﬁle which was similar to that of
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beta-blockers alone. In the presence of a normal or near-normal
QT interval at baseline, and normal or near-normal renal function,
sotalol is a reasonable ﬁrst pharmacological therapy to suppress
recurrences of sustained MMVT. In comparison with beta-blocker
therapy alone, amiodarone has been demonstrated to markedly
reduce recurrent appropriate ICD therapy during 1-year follow-up
when used for secondary prophylaxis (HR 0.30, Po0.001) [138].
However, longer term use of amiodarone for secondary prophy-
laxis is associated with high rates of VT recurrence and serious
adverse effects and may increase mortality compared with placebo
[141,142]. Other AADs that have been used to reduce recurrences
of sustained MMVT include dofetilide [143] and the combination
of mexilitene and amiodarone [144]. Dofetilide is not Food and
Drug Administration approved for use in VAs and is not available
in many parts of the world. Limited experience is also present with
combinations of sotalol and either quinidine or procainamide,
[145] or amiodarone plus mexiletine plus either quinidine or
procainamide [146].
4.3.3. Implantable cardioverter-deﬁbrillator implantation and
programming
An ICD is indicated for most patients with SHD and sustained VT
[64]. Implantable cardioverter-deﬁbrillator implantation has been
demonstrated to improve survival in patients with VT and reduced
systolic function [95–97]. Implantable cardioverter-deﬁbrillator
implantation is indicated for patients with sustained MMVT and
myocardial scar, even when systolic function is normal or near-
normal [1] based upon extrapolation from randomized trials including
patients with low EF. Although evidence of mortality beneﬁt is scant in
the absence of severe systolic dysfunction, ICD implantation may
simplify management and follow-up of these patients.
4.3.4. Catheter ablation
Catheter ablation for VT is an important non-pharmacological
alternative or adjunct to AAD therapy [3]. Catheter ablation has been
demonstrated to reduce appropriate ICD shocks for patients with
ischaemic cardiomyopathy when utilized after a ﬁrst presentation
with VA [147]. In patients with prior MI, reduced EF, and haemody-
namically stable VT, catheter ablation signiﬁcantly reduces recur-
rences of VT, with the greatest beneﬁt in patients with EF430%
[148]. Cooled tip catheter ablation was superior to AAD therapy for
reducing recurrences of sustained MMVT in patients with ischaemic
heart disease who had failed amiodarone [149]. Although catheter
ablation reduces recurrences of sustained MMVT in patients with
ischaemic cardiomyopathy, a reduction in mortality has yet to be
demonstrated [150]. Catheter ablation has also been successfully
used in patients with non-ischaemic cardiomyopathy where the
ablation target is often on the epicardial surface of the ventricles
and the procedure may be more complex [151–156]. The long-term
effectiveness of catheter ablation for non-ischaemic cardiomyopa-
thies has been less well studied than for ischaemic cardiomyopathies.
While either catheter ablation or AAD therapy may be used as a
ﬁrst-line therapy for VT in the setting of prior MI, catheter ablation is
the preferred therapy for patients presenting with incessant sus-
tained MMVT. While encouraging, the long-term success of catheter
ablation for sustained MMVT in patients with non-ischaemic cardi-
omyopathy is less well deﬁned than in patients with ischaemic heart
disease [157]. Thus, AAD therapy is often used as ﬁrst-line therapy
with catheter ablation reserved for those with recurrent VT while
receiving medications. Procedural complications with catheter abla-
tion of sustained MMVT in the presence of SHD have generally been
reported in o5% of patients and may include atrioventricular (AV)
conduction block, cardiac perforation, stroke/transient ischaemic
attack, heart failure, or death, usually in o3% of patients [158].
5. Sustained polymorphic ventricular tachycardia/ventricular
ﬁbrillation
Expert consensus recommendations on sustained polymorphic
VT/VF
1. Patients with polymorphic VT or VF should be thoroughly
evaluated for the presence of SHD, inherited arrhythmia
syndromes, early repolarization, coronary artery spasm, and
pro-arrhythmic effects of medications using:
a. Twelve-lead ECG during the arrhythmia (when feasible)
and during normal rhythm. (I) LOE C
b. Echocardiography. (I) LOE B
c. Coronary arteriography. (I) (LOE B)
2. Speciﬁc antiarrhythmic therapies, e.g. quinidine in patients
with idiopathic VF, sodium channel blocker therapy in
patients with long QT syndrome (LQTS) III, intensive
autonomic inhibition in patients with catecholaminergic VTs,
or quinidine in BrS, should be considered in close cooperation
with a specialist in these diseases to reduce the risk of
recurrence as an adjunct to – and rarely as an alternative to –
deﬁbrillator therapy in survivors of polymorphic VAs. Detailed
guidance can be found in the APHRS/EHRA/HRS document on
inherited arrhythmia syndromes. (IIa) LOE B
3. For patients with VT/VF storm, reversible factors such as
electrolyte abnormalities, pro-arrhythmic drugs, ischaemia,
and decompensated chronic heart failure should be corrected.
(I) LOE C
4. Pharmacological suppression of VT/VF storm with beta-
adrenergic blockers, amiodarone, and/or lidocaine should be
considered in all patients. (IIa) LOE C
5. For patients with VT/VF storm in whom pharmacological
suppression has not been effective and who are unstable,
neuraxial modulation, mechanical ventilation, catheter
ablation, and/or anaesthesia may be considered. (IIb) LOE C
6. Catheter ablation of VTs or a triggering focus of VF should be
considered in patients with VT/VF storm when adequate
experience is available. (IIa) LOE C
7. For patients with VT/VF storm and signiﬁcant SHD,
implantation of a LV assist device (LVAD) or heart transplant
evaluation should be considered and discussed early after the
initial event. (IIa) LOE C
Polymorphic ventricular tachycardia is deﬁned as a ventricular
rhythm faster than 100 b.p.m., with clearly deﬁned QRS com-
plexes that change continuously from beat to beat indicating a
changing ventricular activation sequence. The QT interval can
either be normal or prolonged during intervening sinus rhythm
in patients with PMVT. When PMVT occurs in the setting of a
prolonged QT interval and has a distinctive pattern where the
QRS complexes appear to be twisting around the isoelectric
baseline, the arrhythmia is referred to as TdP [159]. In cases of
TdP, a long – short ventricular cycle length typically characterizes
the initiating sequence, and the QT interval is almost always
prolonged during sinus rhythm [160]. Torsades de pointes VT is
strongly associated with drugs or electrolyte abnormalities that
delay repolarization. Thus, the occurrence of this arrhythmia
should always prompt a search for precipitating factors that
should be corrected.
Polymorphic VT has more than one morphologically distinct
QRS complex occurring during the same episode of VT, but the QRS
is not continuously changing. Ventricular ﬁbrillation differs from
PMVT in that VF is a chaotic tachycardia without consistently
identiﬁable QRS complexes. It is important to distinguish PMVT,
TdP, and VF because the mechanisms and the ultimate therapies
for each may differ.
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5.1. Importance and prognosis
Following cardiopulmonary resuscitation and protection of cerebral
function in a patient with VF or sustained PMVT, the initial diagnostic
step is to exclude an acute coronary syndrome (ACS) or MI [161–165].
An ischaemic cause of these arrhythmias is very common and
emergent coronary angiography and revascularization may signiﬁ-
cantly improve prognosis [166]. In the absence of evidence for
myocardial ischaemia, the structure and function of the ventricles
should be assessed with echocardiography. A scheme for a diagnostic
workup is shown in Fig. 6. Patients who have impaired LV systolic
function after MI (LVEF o0.35) are at higher risk of sudden death in
the ﬁrst 3 months and may beneﬁt from a wearable deﬁbrillator. The
LV function should be reassessed 40 days after MI to determine
whether there is an indication for an ICD. Patients who are treated
with coronary revascularization after MI are also at risk, especially if
the LVEF is o0.35. These patients may also beneﬁt from a wearable
deﬁbrillator with reassessment of LV function and the indication for an
ICD at 90 days post-revascularization.
5.1.1. Patients without structural heart disease
Polymorphic VT or VF in the absence of SHD suggests the
presence of an inherited arrhythmia syndrome such as CPVT, the
CAD treatment/prevention
Re-evaluate LV EF after 40
or 90 days**
No ACSACS present
Consider
ICD
SHD
Resuscitation/defibrillation/ACLS
No SHD
Inherited
arrhythmia
syndrome
Reversible cause?
No Yes
Adjuvant therapy to reduce
ICD shocks
Treat reversible
cause / avoidance
of precipitating
factors
EF >35% EF <35%
Medical treatment
If incompletely reversible
Wearable defibrillator for high-risk patients
Fig. 6. Sustained polymorphic ventricular tachycardia / ventricular ﬁbrillation. **LV function should be reassessed at 40 days after MI or 90 days after revascularization. ACS,
acute coronary syndrome; ACLS, advance cardiovascular life support; CAD, coronary artery disease; ICD, implantable cardioverter-deﬁbrillator; LVEF, left ventricular ejection
fraction; SHD, structural heart disease.
Table 5
Conditions that can cause PVT/VF in the absence of SHD and potential therapies.
Clues Tests to consider Diagnoses Therapies
Long QT/T-wave alternans ECG/Monitor Congenital LQTS Beta-blockers/stellatectomy TdP
pattern Epinephrine challenge Avoid QT prolonging drugs
History of seizures Genetic testing Mexilitine/ﬂecainide (LTQ3)
Speciﬁc trigger (loud noise) Pacemaker/ICD
Long QT/T-wave alternans ECG/Monitor Acquired LQTS Mgþ þ/Kþ
TdP pattern Stop offending drug
Renal failure Temporary pacing
New medication or drug abuse
AV block ECG/Monitor Bradycardia Pacemaker
Incomplete RBBB with STE in leads V1 – V2 ECG BrS Isoproterenol/quinidine
Fever Drug challenge Anipyretic
Genetic testing Ablation
ICD
Monomorhic PVC trigger ECG/Monitor Focal PVC origin Ablation/ICD
J-point elevation ECG Early repolarization ICD
Ventricular pre-excitation ECG WPW Ablation
Short QT interval ECG Short QTS ICD
Bidirectional VT pattern exercise-induced Digoxin level CPVT Stop digoxin
Exercise test Andersen–Tawil syndrome Beta-blockers/CCBs/ﬂecainide
Genetic testing Digoxin toxicity ICD
STE and chest pain Proactive testing Coronary spasm Vasodilators/coronary stent ICD
Short-coupled PVC trigger ECG/Monitor Idiopathic ICD
BrS, Brugada syndrome; CCBs, calcium channel blockers; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter-deﬁbrillator; LQTS,
longQT syndrome; PVC, premature ventricular complex; RBBB, right bundle branch block; short QTS, short QT syndrome; STE, ST elevation; TdP, torsade de pointes; VT,
ventricular tachycardia; WPW,Wolff-Parkinson-White (syndrome).
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long QT, short QT, Brugada, or ERS (see Table 5) [4]. A resting 12-
lead ECG should be recorded as close as possible to the VA episode
as the chances of making the correct diagnosis is highest at this
time. Recording of all 12 ECG leads over a longer period may be very
useful to identify the morphology and location of PVCs that trigger
PMVT or VF. Use of the Valsalva manoeuvre or high precordial leads
may improve the sensitivity of the 12-lead ECG for detecting such
triggers [167,168]. In addition, the QRS and QT changes occurring
after extrasystoles [169] as well as during standing [170] may help
to identify J-wave abnormalities or abnormalities of the QT interval.
Ambulatory monitoring may help identifying QTc prolongation
during sleep. The role of genetic testing has been recently reviewed
[4] and plays an important part in the evaluation of patients in
whom an inherited arrhythmia syndrome is suspected and for the
family members of patients with these syndromes.
5.1.2. Exercise testing
In the setting of a normal resting 12-lead ECG, the occurrence
of polymorphic PVCs and bidirectional VT during exercise suggests
the diagnosis of CPVT [171–175]. Exercise testing may be helpful to
evaluate the efﬁcacy of beta-blocker in patients with CPVT.
Exercise testing is also useful in the diagnosis of LQTS when the
QT is of borderline duration at rest [176–178]. The absence of QTc
shortening at higher heart rate favours the diagnosis of long QT
[176–178]. The recovery phase of exercise testing may unmask BrS
or LQTS patients with a normal ECG at baseline [179,180].
5.1.3. Pharmacological testing
Different tests have been proposed to evaluate polymorphic VT/
VF in the absence of SHD [181]. The role of these provocative tests
for unmasking inherited arrhythmia syndromes has been recently
extensively reviewed [4]. Intravenous sodium channel blocker
challenge [167] may unmask the BrS. Epinephrine challenge may
help unmasking the LQTS, especially LQTS Types 1 and 2 [182–184].
Isoproterenol challenge has been proposed to identify the early
stages of ARVC, though this is rarely used in modern practice [185]. It
can also be an option for familial screening of CPVT when stress
testing is negative. Adenosine may be used to unmask preexcitation in
patients with the Wolff–Parkinson–White (WPW) syndrome where
the diagnosis is unclear during baseline electrocardiographic record-
ings [186].
5.1.4. Patients with structural heart disease
The resting ECG evidence of ischaemia, injury, or infarction, see
Table 6.
Acute coronary syndromes and old Q-wave MI are the principal
causes of PMVT/VF associated with a normal QTc interval [165]. In
addition, transient myocardial ischaemia may induce PMVT or VF,
especially during conditions of stress or exercise. The presence of ST
depression, elevation, or Q-waves in a patient with PMVT or VF should
lead to prompt coronary angiography. In the absence of acute ECG
evidence of ischaemia or injury, an invasive or noninvasive evaluation
of coronary artery perfusion is indicated. It should be noted that LV
and RV function may be depressed immediately after cardiac arrest
and may markedly improve over a period of days to weeks. A
prolonged or fragmented QRS (fQRS) is a predictor of SCD, appropriate
ICD shocks, and all-cause mortality in patients with ischaemic
cardiomyopathy [187,188]. The presence of fQRS in patients with left
bundle branch block (LBBB) is of particular prognostic signiﬁcance.
The resting ECG may strongly suggest the diagnosis of a dilated
cardiomyopathy when the QRS is prolonged or ARVC when epsilon
waves or localized QRS duration Z110ms are recorded in surface
leads V1, V2, or V3, with inverted T-waves in V2 and V3 [4]. The
presence of PVCs with a LBBB morphology and QRS axis of 901 to
þ1101 also suggests ARVC. In HCM patients, LVH may be associated
with pathological Q-waves, giant (Z10mm) T-negative wave, or ST
depression.
5.2. Treatment
5.2.1. Implantable cardioverter-deﬁbrillator therapy
The ICD is the primary therapy for patients with sustained PMVTor
VF when there is no completely reversible cause [4,189].
5.2.2. Antiarrhythmic drug therapy
While beta-adrenergic blockers may help to stabilize patients
during acute ischaemia, the primary therapy for ischaemia-
induced PMVT or VF is coronary revascularization. Beta-blockers
are recommended for patients with LQTS and CPVT [4,190–192]. In
Table 6
Conditions that can cause PVT/VF in patients with SHD and potential therapies.
Clues Tests to consider Diagnoses Therapies
ECG evidence of ischaemia, injury, or infarction Stress test Coronary artery disease Coronary revascularization
Angina/heart failure Coronary angiography Post-myocardial infarction Beta-blockers
Prior coronary revascularization Echo/MRI Sotalol/amiodarone
Intra-aortic balloon pump ICD
Heart failure Echo/MRI Dilated non-ischaemic cardiomyopathy Avoid cardiotoxins
Alcoholism Coronary angiography Beta-blockers
Sotalol/amiodarone/ICD
Systolic murmur Echo/MRI Hypertrophic cardiomyopathy Beta-blockers
Syncope Genetic testing Sotalol/amiodarone/ICD
Family history of sudden death
Left ventricular hypertrophy
Family history of sudden death Echo/MRI Arrhythmogenic cardiomyopathy Beta-blockers
Epsilon wave Genetic testing Sotalol/amiodarone/ICD
Pulmonary symptoms Echo/MRI Sarcoidosis Immunosuppresion
Dermatitis Chest CT Beta-blockers
Tissue biopsy Sotalol/amiodarone/ICD
Recent ﬂu-like illness Serology Myocartitis Beta-blockers
Cardiac biopsy Sotalol/amiodarone/ICD
Echo/MRI
Mid-systolic click Echo/MRI Mitral valve prolapse Beta-blockers
Systolic murmur Sotalol/amiodarone/ICD
Marfanoid body habitus
CT, computed tomography; ICD, implantable cardioverter-deﬁbrillator; MRI, magnetic resonance imaging.
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small case series, quinidine has been shown to be effective for
preventing polymorphic VT/VF recurrence in idiopathic VF, BrS,
short QT syndrome, and ERS [193–196]. Although calcium channel
blockers (verapamil) in combination with beta-blockers have been
proposed for treatment of CPVT, [197,198] their efﬁcacy seems
quite limited. Flecainide may be considered in association with
beta-blockers in case of recurring polymorphic VT/VF in the
setting of CPVT [199] and LQT3 [200].
5.2.3. Catheter ablation
Catheter ablation may be considered for patients with recurrent
PMVT or VF when there is a consistent PVC morphology (or a limited
number of morphologies) that trigger these arrhythmias [201–208].
When a patient has polymorphic VT/VF induced by the same PVC
morphology, the target of catheter ablation is usually a rapidly ﬁring
focus situated in the Purkinje network of either the RV or LV [204].
These Purkinje ﬁbres may induce PMVT or VF in patients without SHD
or in patients with prior MI [204,206]. Purkinje network triggers of
polymorphic VT or VF are characterized by episodes of frequent
arrhythmias usually with the same initiating QRS morphology that is
relatively narrow. Patients presenting with this syndrome should be
monitored, ideally with continuous 12-lead electrocardiography, to
identify the triggering PVC morphology. If possible, catheter ablation
should be performed during a period of increased arrhythmia fre-
quency to maximize the chances of recording electrograms from the
triggering focus. In cases of recurrent polymorphic VT/VF in patients
with the BrS, an epicardial substrate involving the RVOT may be
amenable to catheter ablation [209,210]. Even when catheter ablation
of foci triggering PMVT or VF has been successful, an ICD remains
indicated [204].
6. The resuscitated cardiac arrest survivor
Patients who are resuscitated from cardiac arrest must be
rapidly evaluated for the presence of SHD, an inherited arrhythmia
syndrome, a triggering VA focus, or a non-cardiac cause (see
Fig. 6). Immediately following resuscitation, the clinical focus must
be to minimize cerebral damage, often with the use of therapeutic
hypothermia [161–164]. Evidence of MI or ischaemia usually
requires prompt coronary angiography and revascularization
[166]. In addition, the function of both ventricles should be
evaluated with echocardiography. These considerations have been
discussed in detail in the preceding sections.
6.1. Ventricular tachycardia/ventricular ﬁbrillation storm
Ventricular tachycardia/ventricular ﬁbrillation storm represents
a true medical emergency that requires a multi-disciplinary
approach to care (Table 7) [70,211–231]. Ventricular tachycardia/
ventricular ﬁbrillation storm is generally deﬁned as the occurrence
of three or more episodes of VT or VF within 24 h, requiring either
ATP or cardioversion/deﬁbrillation. Upon hospitalization, the
patient's risk should be stratiﬁed according to haemodynamic
tolerance of the clinical VT and co-morbidities [211]. High-risk
patients should be admitted to an intensive care unit and evaluated
for sedation, intubation, and mechanical haemodynamic support.
Acute treatment is aimed to reduce VA episodes and maximize
the chances of survival. For patients with an ICD, the detection
criteria and therapies should be reprogrammed to minimize inap-
propriate shocks, [77] prevent shocks for potentially self-terminating
VTs, and favour ATP therapies when feasible. Even though triggers of
VT/VF storm are only rarely found, [70] patients should be screened
for such reversible causes as electrolyte imbalances, ischaemia, acute
valvular disease, and pro-arrhythmic drugs.
Antiarrhythmic drugs should be used for the acute phase to
stabilize the patient [214,223]. Beta-blockers have improved short-
term outcome [212]. Short-acting drugs, such as esmolol, might be
considered in severely compromised patients, when an acute hypo-
tensive effect is potentially likely [228]. Even in patients already on
oral beta-blocker therapy, intravenous administration of beta-blockers
may help to reduce further ES episodes [213]. Beta-blockers can be
combinedwith amiodarone to improve rhythm stability [212]. Because
intravenous lidocaine is relatively ineffective for termination of
haemodynamically stable VTs and its prophylactic use has been
associated with higher mortality, [214] this agent is a third choice
drug for short-term treatment. In patients with severely impaired LV
systolic function, the use of AADs should be weighed against the risks
of worsening congestive heart failure and pro-arrhythmia.
Catheter ablation should be considered early after hospitalization
(within 48 h) in patients with recurrent shocks despite acute treat-
ment after the correction of metabolic, respiratory, and circulatory
imbalances and a trial of AADs. Catheter ablation has been demon-
strated to restore stable sinus rhythm maintenance during 7 days of
in-hospital monitoring [104]. Complete elimination of VT inducibility
during programmed electrical stimulation after ablation is associated
with reduced VT recurrence during long-term follow-up; prevention
of clinical VT inducibility has also been associated with a signiﬁcant
reduction of cardiac mortality [104]. Beneﬁcial effects of catheter
ablation on VT recurrences and survival are evident both in low-
and high-risk patients [211]. For patients who cannot be stabilized
pharmacologically, neuraxial modulation, such as left cardiac sympa-
thetic denervation (CSD) and spinal cord stimulation, may signiﬁcantly
reduce arrhythmias burden [212,215,216]. This may allow stabilization
before catheter ablation or LVAD implantation. Since VT/VF stormmay
be an indicator of poor prognosis, [217–221] especially in patients with
advanced SHD, early consultation with heart failure specialists should
be considered to evaluate the advisability of mechanical cardiac
support or cardiac transplantation.
6.2. Ventricular arrhythmias in patients with a left ventricular assist
device
Left ventricular assist devices can be used as a bridge to cardiac
transplantation or as a permanent, destination therapy for congestive
heart failure. Despite their effectiveness, VAs occur in 25–59% of
patients after LVAD implantation and are associated with a markedly
increased risk of ICD shocks and overall mortality [230–241]. Pre-
operative VAs are the strongest predictor of VT or VF after LVAD
implantation (HR 13.7) [233]. For patients with pre-operative VAs, the
risk of post-operative VT or VF is 50% within the ﬁrst 18 months
after LVAD implantation [232,233,242]. Although LVADs provide
haemodynamic support during VAs, patients may experience palpita-
tions, dyspnoea, and right heart failure. Post-operative VT and VF in
LVAD recipients tend to be refractory to AAD therapy and may require
catheter ablation [230,237,243–247]. Since many forms of VT in
patients with non-ischaemic dilated cardiomyopathy have critical
zones of reentrant circuits in the subepicardial myocardium, the
Table 7
Management of VT/VF storm.
Intensive care unit admission
Device reprogramming
Correct underlying problems (ischaemia, electrolyte disturbances,
pro-arrhythmic drugs)
Beta-blockade
Antiarrhythmic therapy
Sedation, intubation/deep sedation
Mechanical haemodynamic support (intra-aortic balloon pump)
Neuraxial modulation (thoracic epidural anesthesia, cardiac sympathetic
denervation)
Catheter ablation (any time it is feasible)
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postoperative pericardial scarring produced by LVAD implantation
renders post-operative epicardial access for ablation very difﬁcult.
Thus, patients with non-ischaemic dilated cardiomyopathies who have
pre-operative VTmay beneﬁt from concomitant surgical ablation of VT
at the time of LVAD implantation [248,249].
7. Ventricular arrhythmias in congenital heart disease
Expert consensus recommendations on VAs in CHD
(1) Electrophysiological testing is indicated in adults with
unexplained syncope and ‘high-risk’ CHD substrates
associated with primary VAs or poorly tolerated atrial
tachyarrhythmias, such as tetralogy of Fallot, transposition
of the great arteries with atrial switch surgery, or
signiﬁcant systemic or single ventricular dysfunction.
(I) LOE C.
(2) In patients with CHD who have an implanted deﬁbrillator
and recurrent MMVT, VT storm, or multiple appropriate
shocks, additional therapy including ATP, treatment with
antiarrhythmic agents, and/or catheter ablation is indicated
as adjunctive therapy to reduce the arrhythmia episodes.
These therapies should be decided and initiated in an
adequately trained centre. (I) LOE C
(3) In patients with CHD and sustained VAs who require surgical
haemodynamic interventions, pre-operative electrophysiological
testing and intra-operative ablation should be considered when
adequate expertise is available. (IIa) LOE C
(4) Patients with good ventricular function, who are
asymptomatic, have normal or near-normal ventricular
haemodynamics and low-risk subtypes of CHD may
reasonably be followed without advanced therapy and
invasive evaluation despite the presence of moderately
frequent and/or complex ventricular ectopy. (IIb) LOE C
(5) Catheter ablation may be appropriate for patients with CHD
who have newly recognized or progressive ventricular
dysfunction and a high burden of monomorphic ventricular
ectopy. (IIb) LOE C
Ventricular arrhythmias are common in patients with CHD,
often encountered as asymptomatic ﬁndings of PVCs and NSVT
[250–254] on routine monitoring studies, and sometimes requir-
ing treatment [255]. Ventricular arrhythmias may occur in any
con-genital defect, but the most common is tetralogy of Fallot and
its variants, a malformation that has a long history of surgical
repair, is prevalent, and often arrhythmogenic (Table 8 and Fig. 7).
Table 8
Arrhythmia considerations in selected congenital heart disease.
Ventriculotomy RV pressure/volume overload SVT VT Bradycardia Systemic ventricle
Tetralogy of Fallot þ þ þ þþþ þ þ þ LV
Atrial switch for d-TGA þ/ þþ þþþ þ þþ RV
Ebstein's disease þ/ þþ þþþ þ þ LV
Arterial switch for d-TGA þ/  þ þ  LV
Single ventricle  þþ þþþ þ þþ Either
Simple repairs      LV
d-TGA, transposition of the great vessels; LV, left ventricle; RV, right ventricle; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
SVT includes atrial reentry in addition to accessory pathway mediated and atrioventricular nodal reentrant tachycardia.
Bradycardia includes relative frequency of heart block and signiﬁcant sinus node dysfunction that may require pacing/limit drug therapy.
Frequent
SMVT
ICD Programmedstimulation
Atrial reentry
tachycardia
Syncope
sustained palpitations
SMVT
cardiac arrest
Minor symptoms /
asymptomatic
Ambulatory ECG monitoring
VT/VF
induced
VT/VF not
induced
Multiple risk
factors
Frequent
PMVT
Antiarrhythmic drugs, ablation, and/or 
ATP as appropriate
Clinical presentation
Infrequent isolated ectopy, rare non-
sustained VT without symptoms
Simple CHD2Complex CHD1
Consider beta-blockade
Standard follow-upCHD specialist center
periodic  reevaluation
Symptoms
planned surgery
Risk profile
Fig. 7. Management of VAs in CHD. ATP, antitachycardia pacing; CHD, congenital heart disease; d-TGA, transposition of the great vessels; ICD, implantable cardioverter-
deﬁbrillator; LVOTO, LV outﬂow tract obstruction; PMVT, polymorphic ventricular tachycardia; SMVT, sustained monomorphic ventricular tachycardia.
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A recent consensus document addresses recognition and manage-
ment details in greater detail [256,257].
The connection between PVCs or NSVT, SMVT, and risk of SCD is
not well established in CHD patients, although occurrence of
sustained VT is generally considered to imply an elevated risk of
SCD. Sustained VT is a rare clinical arrhythmia in CHD, with
relatively few cases reported in large series in recent decades.
Sudden cardiac arrest causes approximately one-ﬁfth of the
mortality in adults with CHD, [258,259] with greater risk noted
in certain types (e.g. tetralogy of Fallot, Ebstein's disease, left-sided
obstructive disease) [260]. However, the annual mortality rates are
low compared with adult populations (0.1–0.3% per patient-year)
[261–264].
Patients with CHD deemed at elevated risk for SCD are
considered for ICD implantation, although this may be difﬁcult
in small patients or those with malformations that limit lead
placement. Indications for ICD implantation in CHD are largely
based on expert consensus. Risk assessment strategies, [265–270]
descriptions of implantation techniques, [271] and current guide-
lines for ICD implantation in CHD [1,6,272,273] are available from
other sources and not discussed here. A recent consensus docu-
ment addresses recognition and management details in greater
detail [256,257].
7.1. Indications for programmed ventricular stimulation in patients
with congenital heart disease
Inducible VAs (VF, MMVT, or PMVT) predict increased risk of
both arrhythmia event and overall mortality in CHD patients
carefully selected for programmed ventricular stimulation
[265,266,274]. Selection to enhance risk may include arrhythmia
symptoms [275] (sustained palpitations/syncope) and/or combi-
nations of less robust predictors, such as older age, QRS duration
4180 ms, complex ventricular ectopy, RV or LV dysfunction, and
depressed exercise tolerance [276,277]. In older patients with CHD
[274] and in patients with tetralogy of Fallot, [265] positive
ventricular stimulation is associated with increased risk of ICD
use, sudden death, and poor haemodynamic outcome, resulting in
a positive predictive value of 20–60% [266,278]. In contrast, EP
testing in unselected and younger patient groups with CHD
appears to have less predictive value [267,268,279]. Supraventri-
cular arrhythmia, particularly atrial tachycardia, is common in
patients with CHD [255] and may contribute a substantial portion
of inappropriate ICD therapies, [280] suggesting that assessment
for atrial tachycardia should be included when EPSs are performed
in these patients.
Multiple criteria should thus be used to determine which
patients with VAs should undergo EPS, including symptoms,
haemodynamic status, [281,282] and surgical history (ﬂowchart/
Table 9) [269,278,283]. Deferring EPS in favour of clinical surveil-
lance is warranted for patients with favourable risk proﬁles (good
ventricular function, lesser grades of ectopy, minimal arrhythmia
symptoms).
7.2. Management of ventricular tachycardia and premature
ventricular complexes in patients with congenital heart disease
Clinical presentations that indicate the need for therapy of VAs in
patients with CHD include arrhythmia-related symptoms and dete-
rioration of ventricular function. In patients with CHD who have an
implanted ICD, frequent appropriate shocks often require prevention
of recurrences. Strategies for management include suppressive antiar-
rhythmic therapy, ablation (catheter or surgical), and ATP. There are no
prospective studies of sufﬁcient power to be directive of therapy in
this group of patients. Thus, recommendations regarding management
of VA in this patient group are based on expert consensus.
Antiarrhythmic agents are often used to suppress PVCs and
NSVT of lower grades. Efﬁcacy is usually deﬁned as symptomatic
improvement or reduction in ectopic events, but suppression of
PVCs is not known to be associated with change in mortality.
Table 9
Clinical factors to consider when evaluating CHD patient for electrophysiological study.
Findings Response
Highest risk features Sustained MMVT ICD therapy EPS prior if potential for SVT trigger Cardiac arrest
High risk Syncope Sustained palpitations Haemodynamic evaluation and EPS
Intermediate risk Older age at initial repair (41 year) In the presence of multiple risk beta-blocker or EPS
Older age (425–30 years)
Prior palliative procedures Ventriculotomy
RV haemodynamic burden
 RVp 450% systemic
 Moderateþpulmonary insufﬁciency
 RV end-diastolic volumes 4150 mL/m2 (Ref. [280])
 Increased heart size on CXR
 RV function o45%
 QRSd 4180 ms
LV dysfunction (o55% for tetralogy) NSVT on monitoring
 ? signiﬁcance of rare NSVT on CRMD monitoring
Less clear symptoms
VO2 max o20 cc/kg/min
T-wave alternans
Low risk Simple ‘repairs’ without residual
Expected or less isolated ectopy on monitoring No symptoms
Good exercise capacity Good biventricular function
Complicating Features Need for CRMD management Consider staged interventions including follow-up studies after remodeling
Anticipated haemodynamic interventions
 Pulmonary valve replacement
 Tricuspid valvuloplasty
 CRT
CHD, congenital heart disease; CRT, cardiac resynchronisation therapy; CXR, chest X-rays; EPS, electrophysiological study; ICD, implantable cardioverter-deﬁbillator; LV, left
ventricular; MMVT, monomorphic ventricular tachycardia; NSVT, non-sustained ventricular tachycardia; RVp, right ventricular pressure; SVT, supraventricular tachycardia.
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Evidence for safety and efﬁcacy of AAD therapy (e.g. mexiletine,
propafenone, sotalol, and amiodarone) [284–286] is derived from
case series in populations with mixed arrhythmia mechanisms, or
is inferred from studies performed in adult populations, although
amiodarone has also been prospectively studied in an acute setting
in a small number of paediatric patients with VT [287]. These
advanced antiarrhythmic agents are largely reserved for suppres-
sing excessive arrhythmia in patients with ICD therapy or those
where ICD therapy is deferred for anatomical reasons. Program-
ming ICDs to high VF detection rates and long VT detection times
is important to minimize unnecessary ATP or shocks for NSVT that
would have been self-terminating without device intervention.
While there are similarly no prospective data on beta-blockers in
patients with CHD who have VAs, their broad safety proﬁle results
in them being a popular choice to suppress ectopy.
Several studies have documented the feasibility of using catheter
ablation to treat MMVT in patients with CHD [288–291]. Success rates
in these studies have ranged from 60% to 490% case series of 11–20
patients and in one case ablation has been proposed in conjunction
with use of Class III antiarrhythmic agents [292]. Access to the
ventricular endocardiummay be limited by some anatomical abnorm-
alities or surgical corrections. Extrapolating from adult data with
normal cardiac anatomy, in patients with frequent (15% or more)
monomorphic ventricular ectopy and newly recognized or progressive
ventricular dysfunction, ablation of PVCs may be a useful adjunct if
suppressive AAD therapy fails [23,293]. The European Society of
Cardiology guidelines for adults with CHD [6] suggest the ablation
may be reasonable as monotherapy for SMVT.
Recent mapping studies suggest predictable anatomical sub-
strates for reentry in many patients with typical biventricular
anatomy (i.e. that seen after repair of tetralogy of Fallot) [294].
These include the corridor between the tricuspid annulus and the
RVOT, and the infundibular septum. While surgical ablation based
on this anatomical template can be added to surgical repairs, [295]
the efﬁcacy of this approach remains uncertain.
A recent, small study has suggested that ATP may be efﬁcacious
in paediatric and congenital patients with ICDs [296]. The relative
simplicity of this approach in combination with the more compel-
ling evidence derived from adult studies suggest that this should
be considered in all implanted patients.
Ventricular arrhythmias occur more frequently in patients with
signiﬁcant haemodynamic burden. New or increasing VAs should
always trigger a careful evaluation of the underlying haemody-
namic issues [297]. However, correction of haemodynamic pro-
blems alone does not eliminate Vas [298–300].
7.3. Younger children and infants
The writing group has focused on the adult patient. These data
are reasonably extrapolated to the older adolescent. For the
younger adolescent, the school age child and particularly for
infants both the natural history, the risk/beneﬁt calculations for
drugs, ablation, and device therapy may be different. Therefore,
consultation with centres experienced in the management of
children is appropriate. Recent guidelines focus on this particular
population [301].
7.4. Evidence gaps and future research directions
The writing group acknowledges the lack of randomized con-
trolled clinical trials to support many of the recommendations put
forward in this document. While we acknowledge the historical
reasons (see the Introduction section), the writing committee
strongly supports controlled trials in adequately diagnosed con-
temporary patient cohorts. There is ample evidence to support the
use of deﬁbrillators in patients at highest risk for sudden death.
While the initial approach to these patients was done in high-risk
patients, the available data suggest that ECG parameters and/or
cardiac imaging could better deﬁne those patients who will
beneﬁt from a deﬁbrillator, and possibly delineate patient groups
at lower risk who will not. The use of AADs for the suppression
and symptomatic improvement of patients with VAs is in clear
need of controlled trials. Such trials, possibly aiming for sympto-
matic improvement, e.g. measured by patient-reported outcomes
in addition to monitoring of arrhythmia recurrence, seem feasible
in relatively small patient cohorts. Ongoing studies are evaluating
whether early interventional treatment of VAs by catheter ablation
can improve outcomes in patients with an implanted deﬁbrillator.
Furthermore, long-term outcomes after catheter ablation in spe-
ciﬁc disease entities, e.g. RVOT tachycardia or fascicular tachycar-
dia are available and support the use of ablation in these patients.
The role of speciﬁc antiarrhythmic interventions (by AADs or
catheter ablation) in addition to treatment of the underlying heart
disease warrants further clinical research. Furthermore, a con-
temporary description and characterization of the causes and
underlying cardiovascular diseases, including inherited arrhyth-
mogenic syndromes, would allow better strategies to earlier
identify patients at risk for sudden death, thus setting the stage
for intervention trials aimed at reducing sudden death.
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